Characterization and protective activity of a monoclonal antibody against a capsular epitope shared by Streptococcus suis serotypes 1, 2 and 1/2

被引:35
作者
Charland, N [1 ]
Jacques, M [1 ]
Lacouture, S [1 ]
Gottschalk, M [1 ]
机构
[1] UNIV MONTREAL, FAC MED VET, GRP RECH MALAD INFECT PORC, ST HYACINTHE, PQ J2S 7C6, CANADA
来源
MICROBIOLOGY-SGM | 1997年 / 143卷
关键词
Streptococcus suis; capsule; monoclonal antibody; protection; clearance;
D O I
10.1099/00221287-143-11-3607
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
A monoclonal antibody (mAb Z3) was produced using BALB/c mice immunized with whole cells of Streptococcus suis serotype 2 reference strain S735. Screening by dot-ELISA showed that mAb Z3, of isotype IgG2b, reacted only with reference strains and field isolates of S. suis serotypes 1, 2 and 1/2. The recognized epitope was demonstrated to be polysaccharide in nature by periodate oxidation, and located in the capsule, since mAb Z3 reacted with purified capsular material by immunoblotting and was able to stabilize the capsule as shown by electron microscopy. Further characterization indicated that mAb Z3 may react specifically with the sialic acid moiety of the capsule, a common constituent of the polysaccharidic capsular material of the three capsular types, since sialidase-treated cells did not react with mAb Z3 in immunoblotting or indirect ELISA. Purified mAb Z3 was shown to significantly increase the rate of phagocytosis of S. suis cells by porcine monocytes and to activate the clearance of bacteria from the circulation in experimentally infected mice. However, mAb Z3 only offered partial protection to mice challenged with a minimal lethal dose. Thus, even though the capsule of S. suis seems to be an important virulence factor, the epitope recognized by mAb Z3 does not appear to be involved in complete protection against infection.
引用
收藏
页码:3607 / 3614
页数:8
相关论文
共 44 条
  • [1] ARENDS JP, 1988, REV INFECT DIS, V10, P131
  • [2] BEAUDOIN M, 1992, FEMS MICROBIOL LETT, V99, P111, DOI 10.1111/j.1574-6968.1992.tb05552.x
  • [3] BELANGER M, 1992, FEMS MICROBIOL LETT, V97, P119, DOI 10.1111/j.1574-6968.1992.tb05450.x
  • [4] In vitro phagocytosis and survival of Streptococcus suis capsular type 2 inside murine macrophages
    Brazeau, C
    Gottschalk, M
    Vincelette, S
    MartineauDoize, B
    [J]. MICROBIOLOGY-UK, 1996, 142 : 1231 - 1237
  • [5] AGGLUTINATION OF STREPTOCOCCUS-SUIS BY SIALIC ACID-BINDING LECTINS
    CHARLAND, N
    KELLENS, JTC
    CAYA, F
    GOTTSCHALK, M
    [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 1995, 33 (08) : 2220 - 2221
  • [6] Role of capsular sialic acid in virulence and resistance to phagocytosis of Streptococcus suis capsular type 2
    Charland, N
    Kobisch, M
    MartineauDoize, B
    Jacques, M
    Gottschalk, M
    [J]. FEMS IMMUNOLOGY AND MEDICAL MICROBIOLOGY, 1996, 14 (04): : 195 - 203
  • [7] CHARLAND N, 1997, 97 ANN M AM SOC MICR
  • [8] EVALUATION OF IMMUNOTHERAPEUTIC APPROACHES FOR THE POTENTIAL TREATMENT OF INFECTIONS CAUSED BY K1-POSITIVE ESCHERICHIA-COLI
    CROSS, AS
    ZOLLINGER, W
    MANDRELL, R
    GEMSKI, P
    SADOFF, J
    [J]. JOURNAL OF INFECTIOUS DISEASES, 1983, 147 (01) : 68 - 76
  • [9] PROTECTION OF MICE FROM EXPERIMENTAL-INFECTION WITH TYPE-III GROUP B-STREPTOCOCCUS USING MONOCLONAL-ANTIBODIES
    EGAN, ML
    PRITCHARD, DG
    DILLON, HC
    GRAY, BM
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1983, 158 (03) : 1006 - 1011
  • [10] TYPE-SPECIFIC POLYSACCHARIDES OF STREPTOCOCCUS-SUIS
    ELLIOTT, SD
    TAI, JY
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1978, 148 (06) : 1699 - 1704